Long-term follow-up for people treated in a breast cancer trial
Part of Cancer, Skin clinical trials.
This study checks how well a previous early breast cancer treatment works over the long term and monitors safety. It may help you and future patients by providing long-term results from the original trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in an earlier GBG clinical trial for early breast cancer.
- You signed a written consent form before your study data or samples were collected.
- Your prior breast cancer treatment must have been through a GBG trial, not a different sponsor’s trial.
- This is for people with early breast cancer in the original GBG trial, not advanced or metastatic disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
This study looks for tiny bits of cancer DNA in your blood after breast cancer surgery. A blood test called NGS may help doctors find early signs of cancer coming back, and you would give samples and have checkups for 3 years.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial tests a standard follow-up program for people with breast cancer who are getting radiotherapy. It aims to see how well the program supports patients after treatment.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.